Design, Synthesis, and Biological Activity of Prazosin-Related Antagonists. Role of the Piperazine and Furan Units of Prazosin on the Selectivity for α1-Adrenoreceptor Subtypes
- 28 October 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (24) , 4844-4853
- https://doi.org/10.1021/jm9810654
Abstract
Prazosin-related quinazolines 4-20 were synthesized, and their biological profiles at alpha1-adrenoreceptor subtypes were assessed by functional experiments in isolated rat vas deferens (alpha1A), spleen (alpha1B), and aorta (alpha1D) and by binding assays in CHO cells expressing human cloned alpha1-adrenoreceptor subtypes. The replacement of piperazine and furan units of prazosin (1) by 1, 6-hexanediamine and phenyl moieties, respectively, affording 3-20, markedly affected both affinity and selectivity for alpha1-adrenoreceptor subtypes in functional experiments. Cystazosin (3), bearing a cystamine moiety, was a selective alpha1D-adrenoreceptor antagonist being 1 order of magnitude more potent at alpha1D-adrenoreceptors (pA2, 8.54 +/- 0.02) than at the alpha1A- (pA2, 7.53 +/- 0.01) and alpha1B-subtypes (pA2, 7.49 +/- 0. 01). The insertion of substituents on the furan ring of 3, as in compounds 4 and 5, did not improve the selectivity profile. The simultaneous replacement of both piperazine and furan rings of 1 gave 8 which resulted in a potent, selective alpha1B-adrenoreceptor antagonist (85- and 15-fold more potent than at alpha1A- and alpha1D-subtypes, respectively). The insertion of substituents on the benzene ring of 8 affected, according to the type and the position of the substituent, affinity and selectivity for alpha1-adrenoreceptors. Consequently, the insertion of appropriate substituents in the phenyl ring of 8 may represent the basis of designing new selective ligands for alpha1-adrenoreceptor subtypes. Interestingly, the finding that polyamines 11, 16, and 20, bearing a 1,6-hexanediamine moiety, retained high affinity for alpha1-adrenoreceptor subtypes suggests that the substituent did not give rise to negative interactions with the receptor. Finally, binding assays performed with selected quinazolines (2, 3, and 14) produced affinity results, which were not in agreement with the selectivity profiles obtained from functional experiments. This rather surprising and unexpected finding may be explained by considering neutral and negative antagonism.Keywords
This publication has 20 references indexed in Scilit:
- Search for α1-adrenoceptor subtypes selective antagonists: Design, synthesis and biological activity of cystazosin, an antagonistBioorganic & Medicinal Chemistry Letters, 1998
- Search for selective antagonists at α1-adrenoreceptors: neutral or negative antagonism?Il Farmaco, 1998
- 4-Amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]- piperazinyl]-6,7-dimethoxyquinazoline (L-765,314): A Potent and Selective α1b Adrenergic Receptor AntagonistJournal of Medicinal Chemistry, 1998
- Pharmacological Options in the Treatment of Benign Prostatic HyperplasiaJournal of Medicinal Chemistry, 1997
- .alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic ApplicationsJournal of Medicinal Chemistry, 1995
- The α1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aortaLife Sciences, 1995
- Expression of α1-adrenoceptor subtypes in rat tissues: implications for α1-adrenoceptor classificationEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Structure-activity relationships in prazosin-related compounds. Effect of replacing a piperazine ring with an alkanediamine moiety on .alpha.1-adrenoreceptor blocking activityJournal of Medicinal Chemistry, 1989
- The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptorNature, 1988
- pA2 and receptor differentiation: A statistical analysis of competitive antagonismLife Sciences, 1979